On the grounds of their initial experience in the treatment of superficial bladder tumours with unspecific immunotherapy the authors would like to express their confidence in the effectiveness of the intravesical application of BCG vaccine.doi:10.1007/BF02559741C. Damianov...
EP: 1.Overview of Non-Muscle Invasive Bladder Cancer (NMIBC) EP: 2.Appropriate Risk Stratification Intermediate and high-risk Risk Classification EP: 3.Adapting Urology Practices in the Face of BCG Shortages EP: 4.Initial Treatment Selection for NMIBC in the Era of BCG Shortage ...
Findings In this cohort study of 6467 patients with non–muscle-invasive bladder cancer, treatment with intravesical BCG vaccine was associated with a reduced risk of ADRD in the presence of death as a competing risk. However, the risk differences varied with time. Meaning The findings of this...
BCG is a potent immunomodulator, especially of the cell-mediated immunity, and is employed for the treatment of cancers such as that of the bladder30. It is actually being tested for several other cancers31. Recently, BCG was shown to exhibit efficacy against type I diabetes32. This was ...
Bacillus Calmette Guérin (BCG) is currently approved by the FDA for bladder cancer treatment. The mechanism of BCG action in the treatment of IC is unknown, although the modulation of the host immune response by this agent has been proposed. This agent has been employed intravesically in...
Guidelines for the diagnosis, treatment and prevention of leprosy World Health Organization, Geneva (2018) Google Scholar [44] F.J. Moet, D. Pahan, L. Oskam, J.H. Richardus Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy:...
(95% CI 34.9–68.0%). No patient progressed to muscle-invasive bladder cancer in this trial. Adverse events attributed to cretostimogene were low grade, self-limiting and predominantly limited to bladder-related symptoms. A total of 5 out of 35 patients (14.3%) developed grade 3 treatment-...
“One of the limitations of any agents to administer are costs. Bladder cancer is the [costliest] cancer of all cancer types. We need to be more judicious on how we allocate treatment but also to the availability. [Intravesical gemcitabine] is chemotherapeutic agent and does not need to be ...
It therefore should not be used for the prevention of COVID-19 before solid evidence for its effectiveness for this indication is available [47]. Other off-target effects of BCG Previous or concurrent BCG also influences immune responses to other immunisations. For example, when healthy volunteers...
treatment, despite equally restored and long term improved blood sugar control. The BCG-treated type 1 diabetic subjects at year 4 after glucagon challenge had a negligible to no return of clinically significant C-peptide. The C-peptide values after glucagon were in the range of 2–3 pmol/L ...